RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of May. 22, 2024)

View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals Forward Dividend Yield %?

As of today (2024-05-22), the Forward Annual Dividend Yield of RespireRx Pharmaceuticals is 0.00%.

As of today (2024-05-22), the Trailing Annual Dividend Yield of RespireRx Pharmaceuticals is 0.00%.

RSPI's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.555
* Ranked among companies with meaningful Forward Dividend Yield % only.

RespireRx Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of RespireRx Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RespireRx Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Forward Dividend Yield % falls into.

RespireRx Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

RespireRx Pharmaceuticals (OTCPK:RSPI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

RespireRx Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452

Website

http://www.respirerx.com

RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.

Executives

David Dickason	officer: SVP of Pre-Clinical Prod. Dev.	126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones	director, officer: CEO and President	126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J	director, officer: President & CEO	5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr.	officer: SVP - Research & Deleopment	65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin	officer: Controller	33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten	director, officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc	other: Member of a 10% owner group	354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp	other: Member of 10% owner group
Jeff Eliot Margolis	director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group	C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik	other: Member of 10% owner group	C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa	director, officer: Chairman, CEO and President, other: Member of 10% owner group	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc	other: Member of 10% owner group	C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen	other: Member of 10% owner group	12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130